News

Why Does Chloral Hydrate in Small Nucleic Acid Drug Synthesis Deserve Attention? — A Brief Overview of the Value of Ultra-High Purity Dichloroacetic Acid

Small nucleic acid drugs—including ASOs, siRNAs, aptamers, and other modalities—represent a critical class within the gene therapy landscape. In recent years, this field has sustained rapid development, fueled by significant investment and R&D focus, which have kept it under intense industry spotlight. Globally, hundreds of pipeline candidates are progressively expanding from rare diseases into broader indications, such as oncology, chronic liver diseases, and cardiovascular conditions.
Regardless of how targets, delivery vectors, or mechanisms of action evolve, manufacturing small nucleic acid drugs consistently centers on a single core challenge:

Ensuring high purity and stringent impurity control

The synthesis of small nucleic acid drugs requires the cyclic repetition of four core steps—deprotection, coupling, oxidation, and capping. This means that trace reactive impurities exert effects that are continuously amplified over multiple cycles, ultimately leading to a significant reduction in both yield and purity of the final product.

Take a 20-mer oligonucleotide chain as an example: even with a per-cycle coupling efficiency of 98.5%, the theoretical overall yield is only approximately 75.0%. However, if the coupling efficiency is improved to 99.5%, the yield rises to 90.9%. Even a single percentage point of improvement, when magnified through repeated cycles, delivers a substantial gain in final yield.

This is precisely the fundamental reason why raw materials and synthesis reagents for small nucleic acid drug production must meet exceptionally stringent purity requirements.

Chloral Hydrate: A Critical Impurity of Concern in DCA
Dichloroacetic acid (DCA) serves as an indispensable deprotecting agent (DMT-removal reagent) in solid-phase synthesis of oligonucleotides. Its purity directly impacts the quality of the final product.
Of particular concern is the fact that chloral hydrate—the hydrated form of trichloroacetaldehyde—is inevitably generated as a byproduct during DCA synthesis. This impurity has the following effects:
Reduces yield and product purity

Chloral hydrate can become incorporated between the 5′-oxygen and the phosphorus atom of the internucleotide phosphodiester linkage, forming a process-related contaminant. Due to the repetitive cycling nature of oligonucleotide synthesis, this defect is progressively amplified: the longer the oligonucleotide chain, the more severe the impact, and the higher the rejection rate.

Increases purification difficulty

The full-length modified impurities formed by chloral hydrate are highly similar in structure to the target full-length oligonucleotide. Conventional methods such as ion-pair reversed-phase high-performance liquid chromatography (IP-RP-HPLC) and ion-exchange chromatography (IEX) are often inadequate for complete separation.

Drives up R&D and production costs

The modified products generated by the reaction of chloral hydrate impurities with oligonucleotide chains can still participate in subsequent coupling cycles, leading to wasteful consumption of raw materials and reagents. Furthermore, because these full-length modified impurities closely resemble the target product in properties, more complex purification processes must be established to remove them—this not only increases manufacturing and quality control costs but also further reduces the overall yield of the target product.

In the study “Trichloroacetaldehyde modified oligonucleotides,” researchers added 300 ppm of chloral hydrate to a 3% (v/v) solution of dichloroacetic acid in toluene and synthesized a 20-base phosphorothioate oligonucleotide using standard solid-phase phosphoramidite chemistry. The results showed that under these conditions, approximately 2% of nucleic acid molecules underwent chloral modification in each deprotection step.
This demonstrates that even low-level chloral hydrate contamination is magnified by the cyclic nature of oligonucleotide synthesis:

the longer the oligonucleotide chain and the greater the number of synthesis cycles,

the higher the probability of chloral adduct formation and the more complex the structural variety of impurities,

resulting in a more pronounced impact on final product purity.

Therefore, the most reliable and effective solution to the problems caused by chloral hydrate is source control—selecting high-purity dichloroacetic acid reagents with ultra-low residual chloral hydrate content.

 
Hedinger Ultra-High Purity Dichloroacetic Acid

To meet the stringent requirements of the small nucleic acid industry for synthesis reagents, Gencloud has partnered with Hedinger, a European excipient supplier with over a century of heritage, to introduce an ultra-high purity dichloroacetic acid reagent. This product is specifically designed to address the issues caused by chloral hydrate impurities in industrial-grade dichloroacetic acid. With its superior purity and rigorous impurity control, it meets the full-spectrum needs of small nucleic acid drug development, from R&D through to commercial manufacturing.

Key specifications of this dichloroacetic acid product include:

  • Purity ≥ 99.2%

  • Water content ≤ 0.04% (typical test values can be as low as 0.01%)

  • Chloral hydrate ≤ 20 ppm (typical test values < 1 ppm; refer to the attached COA report)

With exceptional impurity control, this ultra-high purity dichloroacetic acid effectively enhances oligonucleotide synthesis yield and product purity, reduces downstream purification process complexity, lowers overall R&D and scale-up production costs, and mitigates risks—ultimately enabling small nucleic acid drug manufacturers to improve quality while reducing production expenses.

If you would like to learn more about product information and documentation, please feel free to contact us at any time.